Strong Topline, FX Gain Help Neimeth Return To Profitability
Neimeth International Pharmaceuticals Plc recovered from a 2024 pretax loss following a strong topline growth and return to foreign exchange (FX) gain, which shielded the drugmaker from rising expenses. The pharmaceutical company’s revenue grew by 64.28 percent to N7.36 billion in 2025,

Follow Us